rozanolixizumab (Pending FDA Approval)

Brand and Other Names:
  • Print
Sections

Dosing & Uses

Myasthenia Gravis

Pending FDA approval for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

Next:

Pharmacology

Mechanism of Action

Antibody that targets the neonatal Fc receptor (FcRn), thereby reducing circulating IgG

Myasthenia gravis is an autoimmune disease in which IgG autoantibodies are formed against the nicotinic acetylcholine receptor (AChR) or other components of the neuromuscular junction

FcRn prolongs IgG half-life; antagonizing FcRc causes IgG catabolism, resulting in reduced overall IgG and pathogenic autoantibody levels, while avoiding widespread immunosuppression

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.